Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063906
Chunk: 259

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 259
---
 December 31, 2022, and 2021 has been omitted, but may be found in “Item 5. Operating And Financial Review And Prospects” in our annual report on Form 20 -Ffor the year ended December 31, 2022, filed with the SEC on April 28, 2023. A. Operating Results Overview We are a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The Company now focuses all of its efforts on R&D and therefore no longer performs any therapeutic services. While the Company may commence therapeutic services in the future, as of December 31, 2024 and the date hereof, it only operates in one segment. Based on our evaluation of preliminary data and our consideration of a number of factors including substantial unmet needs, benefits over existing therapies, potential market size, competition in market, the Company decides how to prioritize its resources among projects. Overall, our rationale for selecting Lead Projects is not based on any mechanical formula or rigid selection criteria, but instead focused on a combination of the factors and individual attributes of the Lead Projects themselves. See “Risk Factors — Risks Related to the Preclinical and Clinical Development of Our Drug Candidates — “Preclinical development is a long, expensive and uncertain process, and we may terminate one or more of our current preclinical development programs.” and “Management has discretion to terminate the development of any of our projects at any time.” Our goal is to develop a broad range of novel and repurposed therapeutics and diagnostics technology across a wide range of disease/therapeutic areas. Key components of our strategy for achieving this goal include: (for details of our strategy, See “Our Strategy”) •Developing therapeutic and diagnostic innovations across a wide range of disease/therapeutic areas; •Selectively expanding our portfolio with potential products that may be able to attain orphan drug designation and/or satisfy current unmet medical needs; •Collaborating with leading academic institutions and CROs; •Expanding our in -housepharmaceutical development center; •Leveraging our management’s expertise, experience, and commercial networks; •Obtaining and leveraging government grants to fund project development. A significant portion of our financial resources have been used to develop our Lead Projects. Our Lead Projects are ALS -4and SACT -1. In March 2023, we announced that